The effectiveness of using a combination of glucocorticosteroid and salicylic acid in the form of a solution for psoriasis vulgaris of the scalp

Psoriasis vulgaris (VP) occupies a leading place among all forms of psoriasis. The difficulty of treating the psoriatic process is associated with damage to the skin of the scalp, genitals, fold areas and nail apparatus. Finding an effective treatment for psoriasis in these difficult areas is an urgent task of modern dermatology. To evaluate the effectiveness of treatment of psoriasis vulgaris of the scalp using a solution containing a combination of glucocorticosteroid and salicylic acid. This article presents three clinical cases from the practice of a dermatovenerologist. Patients with vulgar psoriasis, predominantly affecting the scalp, were prescribed an Akriderm SK solution containing 0.05% betamethasone and 2% salicylic acid 2 times a day for 3 weeks in topical monotherapy or in combination with systemic therapy. As a result of the therapy, after 14 days, resolution of psoriatic plaques on the scalp was noted; after 21 days of treatment, residual mild erythema was noted, which subjectively did not bother the patients. The article demonstrates the clinical effectiveness of combination topical therapy using salicylic acid and betamethasone in the form of Akriderm SK solution for the treatment of psoriasis vulgaris of the scalp. The combination of these substances in the form of a solution has shown great effectiveness in the treatment of this localization of psoriasis.

1. Matushevskaya EV, Konovalova MV, Vladimirova EV, Svirshchevskaya EV. Pathogenesis and therapy of psoriasis and psoriatic arthritis. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(5):626–634. (In Russ.) https://doi.org/10.17116/klinderma201918051626.

2. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. https://doi.org/10.1016/j.jaad.2018.06.027.

3. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. https://doi.org/10.1002/art.40726.

4. Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R et al. Longterm safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–285. https://doi.org/10.1016/j.jaad.2018.09.002.

5. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/recomend/234_2.

6. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.

7. Benhadou F, Mintoff D, Del Marmol V. Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger? Dermatology. 2019;235(2):91–100. https://doi.org/10.1159/000495291.

8. Stewart CR, Algu L, Kamran R, Leveille CF, Abid K, Rae C, Lipner SR. The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review. Skin Appendage Disord. 2021;7(2):83–89. https://doi.org/10.1159/000512688.

9. Meneguin S, de Godoy NA, Pollo CF, Miot HA, de Oliveira C. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatol. 2020;20(1):22. https://doi.org/10.1186/s12895-020-00116-9.

10. Egeberg А, See К, Garrelts А, Burge R. Epidemiology of psoriasis in hardtotreat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https://doi.org/10.1186/s12895-020-00099-7.

11. Nakamura M, Koo J. Safety considerations with combination therapies for psoriasis. Expert Opin Drug Saf. 2020;19(4):489–498. https://doi.org/10.1080/14740338.2020.1722640.

12. Bernardini N, Skroza N, Tolino E, Marchesiello A, Mambrin A, Balduzzi V et al. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study. Clin Ter. 2020;171(4): e310–e315. https://doi.org/10.7417/CT.2020.2234.

13. Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatol Ther. 2021;11(3):799–831. https://doi.org/10.1007/s13555-021-00523-x.

14. Rigopoulos D, Rompoti N, Gregoriou S. Management of Nail Psoriasis. Dermatol Clin. 2021;39(2):211–220. https://doi.org/10.1016/j.det.2020.12.014.

15. Platonova AV, Zhukov AS, Khairutdinov VR, Samtsov AV. Psoriatic onychodystrophy: indices for assessing the severity of psoriatic onychodystrophy (part 2). Vestnik Dermatologii i Venerologii. 2019;95(1):9–14. (In Russ.) https://doi.org/10.25208/0042-4609-2019-95-1-9-14.